A team in Montreal has been incredibly busy developing what they call a personalized anti-cancer vaccine, one that the researchers have found actually work in mice.
Marie-Claude Bourgeois-Daigneault and her team of scientists from the University of Montreal Hospital Research Centre (CRCHUM) have been working to tweak viruses so that they will be made specific to particular tumor cells.
When these viruses, which are called oncolytic viruses, are within a patient’s body, they then manage to infect and destroy the cancer cells while avoiding harming the healthy cells. The viruses have the ability to trigger the immune system so that they will be able to recognize and kill the malignant cells. Simply explained, this process is called immunotherapy.
The researchers show in their study published in Nature journal how they were able to design an personalized and highly effective vaccine ‘by combining oncolytic viruses with small synthetic molecules (peptides) specific to the targeted cancer.’
When asked about the study findings and the way the team of Bourgeois-Daigneault handled their work, she had a few things to say. She was asked particular questions by the team at Good News Network, and her responses are below.
GGN asked the question: In your study, you use oncolytic viruses as anti-cancer vaccine adjuvants to immunize mice. How do you do it?
According to Bourgeois-Daigneault, “For a vaccine to induce an immune response, it has to contain elements that stimulate the cells of the immune system—the famous white blood cells. These elements, called adjuvants, are ingredients in all vaccines. They allow the human body to perceive potential danger and contain the threat by sending its army of immune cells.”
“Our approach consists of using oncolytic viruses to stimulate this immune response and direct it towards the cancer. To succeed, we create a vaccine by mixing viruses with synthetic peptides (antigens) that resemble the targeted cancer.”
“Because it’s true that, to be effective, the vaccine has to be personalized for each patient, based on the mutations specific to each cancer cell. Thanks to the identification work done by other research teams, we can predict what peptides to use for each patient through the information obtained from a biopsy.”
“The advantage of our approach is that the oncolytic viruses themselves have the power to kill the cancer. We can thus attack the cancer on two fronts: kill it directly with the virus and induce an immune response, thanks not only to the virus, but to the vaccine as well.”
“On our mice, we were able to show the efficacy of the resulting immunization.”
The next question GGN asked her was: What sets your vaccine strategy apart from clinical trials currently being conducted by other teams?
She explains, “The other clinically tested personalized anti-cancer vaccines don’t use oncolytic viruses as vaccination adjuvants. Therefore, their adjuvant doesn’t have direct anti-cancer effects whereas, in our case, our viruses can destroy the cancer.”
“An anti-cancer vaccine using oncolytic viruses is currently being tested in Canada and the U.S. However, it is not personalized. Instead, it targets certain specific cancers that have an antigen in common. By targeting this antigen, the vaccine induces an immune response.”
“In this case, the oncolytic viruses have to be genetically modified to allow for the insertion of the antigen into the genome of the viruses. This is very different from our approach. We can target all cancers without genetic modification. A little like putting together Lego—it’s a matter of mixing synthetic peptides resembling the cancer with the chosen virus. It will be a lot easier to implement in a clinical setting.”
The third question GGN asked the scientist was: What challenges need to be addressed before your personalized anti-cancer vaccination approach can be translated to clinical practice?
Bourgeois-Daigneault iterates, “The main challenge is to identify the mutations that we want to vaccinate against. Because a cancer is unique in its tens or hundreds of mutations, but only a few of them, once targeted, will have a therapeutic effect and allow us to eliminate it.”
“The identification of these mutations is the key step that still has to be optimized. Fortunately, many groups are working in this area.”
Recommended For You
